Navigation Links
Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention

Chalfont, PA (PRWEB) June 28, 2012

Genomind will demonstrate support for the millions of Americans affected by mental illness by participating in the National Alliance on Mental Illness (NAMI) 2012 National Convention. This marks the second year Genomind is appearing at NAMI; last year the company gave a presentation on emerging technologies in mental health.

The theme of this year’s meeting is “Think, Learn and Live: Wellness, Resiliency and Recovery.” It is a message that resonates with Genomind since the company was founded with the ultimate goal of improving patients’ lives - particularly the lives of patients with difficult-to-treat psychiatric conditions. Its core product, the Genecept™ Assay, is a simple to use, saliva-based tool to inform clinician treatment decision-making for a range of psychiatric disorders, including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD.

“We are proud to support NAMI,” said Dr. Jay Lombard, chief scientific officer and co-founder of Genomind. “It is a wonderful organization that is devoted to helping improve the lives of the over 1 in 4 adults and 1 in 10 children across America affected by mental illness. We share NAMI’s commitment to bringing advancements in research to clinical practice and patients.”

The convention will be held at the Sheraton Seattle from June 27-30. Genomind will exhibit the Genecept Assay in Booth 206. For more information about this year’s convention, please visit

About NAMI
NAMI is the nation's largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness. NAMI advocates for access to services, treatment, supports and research and is steadfast in its commitment to raising awareness and building a community of hope. For more information, please visit

About Genomind
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
2. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
3. ViroPharma to Participate in Two December Healthcare Investor Conferences
4. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
5. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
6. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
7. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
8. Promoting the States Quality of Life, New Jersey Symphony Orchestra to Perform at BIO International Convention
9. International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
10. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
11. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
Breaking Biology News(10 mins):